Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (Nasdaq: NTLA) reported Q1 2026 results and major clinical milestones. Cash, cash equivalents and marketable securities were $517.2M on March 31, 2026, plus ~$207M gross from an April equity offering, funding operations at least into 2028.
Lonvo-z achieved positive Phase 3 HAELO topline data in HAE, meeting its primary and all key secondary endpoints and supporting a rolling BLA, with a potential U.S. launch in the first half of 2027. The FDA lifted clinical holds on Phase 3 nex-z ATTR trials, and Q1 2026 net loss narrowed to $96.2M from $114.3M year over year.
Intellia Therapeutics (Nasdaq: NTLA) said management will participate in three upcoming investor fireside chats: Bank of America Securities Health Care Conference on May 12, 2026 (3:40 p.m. PT, Las Vegas); RBC Capital Markets Global Healthcare Conference on May 20, 2026 (2:35 p.m. ET, New York); and Jefferies Global Healthcare Conference on June 3, 2026 (4:55 p.m. ET, New York).
All sessions will be webcast live with replays available for approximately 90 days on Intellia’s Events and Presentations page at intelliatx.com.
Intellia Therapeutics (Nasdaq: NTLA) announced on May 1, 2026 that it granted inducement awards to 43 new employees under its 2024 Inducement Plan.
The awards are time-based RSUs totaling 208,850 shares, vesting one-third annually over three years, and were approved under Nasdaq Listing Rule 5635(c)(4) by the compensation committee.
Intellia Therapeutics (Nasdaq: NTLA) announced the pricing of an underwritten public offering of 16,744,187 common shares at $10.75 per share, with gross proceeds of approximately $180 million before underwriting discounts and expenses.
The company granted underwriters a 30-day option to buy up to 2,511,628 additional shares. Jefferies, Goldman Sachs and Citigroup are joint book-runners. The offering is subject to market and other conditions and is being made under an automatic shelf registration on Form S-3ASR.
Intellia (Nasdaq: NTLA) announced an underwritten public offering of $150 million of common stock, with a 30-day underwriter option to purchase up to an additional 15% of the shares. All offered shares are to be sold by Intellia.
The offering is being led by Jefferies, Goldman Sachs and Citigroup, is subject to market and other conditions, and will be made under an automatic shelf registration on Form S-3ASR (File No. 333-275740). A preliminary prospectus supplement will be filed with the SEC.
Intellia Therapeutics (NASDAQ: NTLA) reported positive topline Phase 3 HAELO results for one-time in vivo gene edit lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE).
In 80 patients, a single 50 mg infusion reduced attacks by 87% versus placebo over a six-month efficacy period (mean monthly attack rate 0.26 vs 2.10; p<0.0001), with 62% attack- and therapy-free in the lonvo-z arm. Favorable safety observed; no serious adverse events in lonvo-z arm as of data cutoff (Feb 10, 2026). Rolling BLA to FDA initiated; potential U.S. launch in H1 2027 if approved.
Intellia Therapeutics (Nasdaq: NTLA) initiated a rolling BLA submission to the FDA for lonvo-z (formerly NTLA-2002) as a one-time in vivo CRISPR treatment for hereditary angioedema (HAE).
Phase 3 HAELO met its primary and all key secondary endpoints, showing most patients were free from HAE attacks and ongoing therapy during the six-month primary period. Intellia expects to complete the BLA in the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027. Lonvo-z holds RMAT designation and participated in the FDA CMC pilot to help expedite review.
Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026. This is described as the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate.
The company will host a webcast at 8:00 a.m. ET on April 27, 2026 to discuss the topline results; a replay will be available for approximately 90 days.
Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan. The awards comprised 67,150 RSUs vesting one-third annually over three years and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
All equity vesting is conditioned on continued service through vesting dates; awards were granted outside stockholder-approved plans pursuant to the inducement plan adopted by the board in June 2024.
Intellia Therapeutics (Nasdaq: NTLA) announced on March 6, 2026 that it granted inducement awards to six new employees under its 2024 Inducement Plan.
The awards were time-based restricted stock units totaling 16,500 shares, with one-third vesting annually over three years, granted March 1, 2026 and approved under Nasdaq Listing Rule 5635(c)(4).